HRP20140055T1 - Derivati aminotiazola i njihove uporabe kao antibakterijskog sredstva - Google Patents
Derivati aminotiazola i njihove uporabe kao antibakterijskog sredstva Download PDFInfo
- Publication number
- HRP20140055T1 HRP20140055T1 HRP20140055TT HRP20140055T HRP20140055T1 HR P20140055 T1 HRP20140055 T1 HR P20140055T1 HR P20140055T T HRP20140055T T HR P20140055TT HR P20140055 T HRP20140055 T HR P20140055T HR P20140055 T1 HRP20140055 T1 HR P20140055T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- image
- alkyl
- compound according
- compound
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000186427 Cutibacterium acnes Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 claims 1
- 241000588767 Proteus vulgaris Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940055019 propionibacterium acne Drugs 0.000 claims 1
- 229940007042 proteus vulgaris Drugs 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (14)
1. Spoj, naznačen time, da ima formulu VI:
[image]
i njegove farmaceutski prihvatljive soli, njegovi enantiomeri, stereoizomeri, rotameri, tautomeri, dijastereomeri, atropizomeri ili racemati, uključujući njegove piridin-N-okside;
pri čemu je R odabran iz skupine koju čine N (R1)2 i N (R1)-A-G-Q-J;
A je veza ili je odabran iz skupine koju čine -C(O)-, -C(O)C(O)-, -C(O)O-, -C(O)N(R8a)-, -S(O)2-, -S(O)-, -S(O)2N(R8a)-, -S(O)N(R8a)-, -C(=NR8)N(R8a)-, -C(=NR8)N(R8a)C(O)-, -C(=NR8)-;
G je odsutan ili je odabran iz skupine koju čine -[C (Ra) (Rb) ]x-, -[CRa) (Rb) ]x-C (Ra) =C (Ra)-[C (Ra) (Rb)]y-, -[C (Ra) (Rb) ]x-O-[C (Ra) (Rb) ]y-, i -[C (Ra) (Rb) ]x-N (R8a)-[C (Ra) (Rb) ]y-, ili je odabran iz skupine koju čine -(cikloalkil)-, -(heterocikl) -, -(aril)- i -(heteroaril)-, gdje svaki od njih ima 0 do 4 supstituenta;
Q je odsutan ili je odabran iz skupine koju čine -C (O)-[C (Ra) (Rb) ]x-, -C (O)-[C (Ra) (Rb) ]x- C (Ra) =C (Ra)[C (Ra) (Rb) ]y-, -C (O)- [C (Ra) (Rb) ]x-O-[C (Ra) (Rb) ]y-, i -C (O)-{N (R8a)-[C (Ra) (Rb) ]y}p-, ili je odabran iz skupine koju čine -(cikloalkil)-, -(heterocikl)-, -(aril) -, -(heteroaril)-, -C (O)-(cikloalkil)-, -C (O)-(heterocikl)-, -C (O)-(aril)-, i -C (O)-(heteroaril), gdje svaki od njih ima 0 do 4 supstituenta;
J je odabran iz skupine koju čine H, C1-4alkil, halogen, C1-4alkoksi, hidroksi, amino, mono- i di-C1-4alkilamino, tri-C1-4alkilamonijak, N (R8a) C (O) C1-4alkil, CO2H, C (=O) N (R8a)2, CH2CO2H, CH2C (=O) N(R8a)2, CO2-C1-4alkil, C (O) C1-4alkil, P (O) (OH)2, P (P) (O-C1-4alkil)2, C0-4alkilen-(cikloalkil) i C0-4alkilen-(heterocikl),
gdje heterocikl može biti supstituiran od 0 do 4 puta;
Raje odabran iz skupine koju čine H, alkil, F, CO2H, CO2-alkil, -N (R1)2, -OR1, -(CH2)0-4-J i -R4b;
Rb je odabran iz skupine koju čine H, alkil i F;
p je 0, 1, 2 ili 3;
x i y svaki put kada se pojavljuju, neovisno su odabrani od cijelih brojeva 0 do 10;
R1 je svaki put kada se pojavljuje, neovisno odabran od -H, alkila supstituiranog s J, i -R4b.
R2 je vodik, C1-6alkil, hidroksiC1-6alkil, C1-6alkoksiC0-6alkil, C3-7cikloakilC0-4alkil, arilC0-4alkil, ili je ostatak formule:
[image]
R2aje odabran iz skupine koju čine H, C1-6alkil, OH, OR4a, OC (O) R4a, OC (O) N (R8a)2 i N (R8a)2;
R2bje H ili C1-6alkil, ili ako se uzmu R2a i R2bzajedno u kombinaciji, tvore okso ili imino skupinu;
R3 i R12 su svaki neovisno odabrani iz skupine koju čine H, halogen, OR4b, -G-J, i N (R8a)2;
R4a je odabran iz skupine koju čine H i alkil;
R4b je alkil;
R5 je odabran iz skupine koju čine H, alkil i R4b;
R8 je odabran iz skupine koju čine H, CN, NO2, C1-6alkil, C3-7cikloalkil i SO2- C1-6alkil;
R8a je odabran iz skupine koju čine H, C1-6alkil, C3-7cikloalkil, C1-6alkil supstituiran s J, te R4b.
2. Spoj prema zahtjevu 1, naznačen time, da R2 je ostatak formule:
[image]
gdje
R2a je odabran iz skupine koju čine H, C1-6alkil, OH, OR4a, OC (O) R4a, OC (O) N (R8a)2 i
N (R8a)2; i R2b je H ili C1-6alkil, ili ako se uzmu R2a i R2b zajedno u kombinaciji, tvore okso ili imino skupinu.
3. Spoj prema zahtjevu 1, naznačen time, da R je N (R1)-A-G-Q-J, R1 je H i A-G-Q-J zajedno tvore H, ili zajedno tvore funkcionalnu skupinu odabranu iz skupine koju čine:
[image]
[image]
4. Spoj prema zahtjevu 1, naznačen time, da R je N (R1)- A- G- Q- J, R1 je H i A-G-Q-J zajedno tvore funkcionalnu skupinu odabranu iz skupine koju čine
[image]
[image]
pri čemu je R13odabran iz skupine koju čine vodik, hidroksimetil i aminometil ili je odabran iz skupine koju čine:
[image]
[image]
5. Spoj prema zahtjevu 1, naznačen time, da R2a je OH ili OAc, a R2b je H.
6. Spoj prema zahtjevu 1, naznačen time, da A je C (O), C (O) O ili C (O) NH;
G je C4-7cikloalkil; Q je odsutan; te J je CO2H ili CO2C1-4alkil.
7. Spoj prema zahtjevu 1, naznačen time, da je formula VI predstavljena spojem formule VII:
[image]
i njegova farmaceutski prihvatljiva sol.
8. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
9. Spoj prema bilo kojem zahtjevu od 1 do 8, naznačen time, da se upotrebljava za liječenje bolesti.
10. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 8 i barem jedan farmaceutski prihvatljiv nosač ili razrjeđivač.
11. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava za liječenje bakterijske infekcije; ili je spoj prema bilo kojem od zahtjeva 1 do 8 za uporabu u liječenju, inhibiranju ili prevenciji djelovanja bakterija kod subjekta, pri čemu spoj tijesno surađuje s bilo kojem ciljem u životnom ciklusu bakterije.
12. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava za liječenje, inhibiciju ili prevenciju bakterijskih infekcija uključujući infekcije koje su uzrokovane sojevima bakterija otpornima na veći broj lijekova, kako slijedi: Staphyloccocus aureus, Streptococcus pneumoniae, Mycobacterium tuberculosis i Enterococci, Clostridium difficile, Propionibacterium acnes, Bacteroides fagiles, Neisseria gonorrhoeae, Branhamella catarrhalis, Haemophilus influenzae, E.coli, Pseudomonas aeruginosa, Proteus vulgaris, Klebsiella pneumonia i Chlamydia trachomatis.
13. Spoj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u kombinaciji s farmaceutski učinkovitom količinom dodatnog terapeutskog sredstva u svrhu liječenja bakterijske infekcije.
14. Pakirano sredstvo za liječenje bakterijske infekcije, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 8, kao i zapakirane upute za uporabu učinkovite količine toga spoja u svrhu liječenja bakterijske infekcije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80969306P | 2006-05-31 | 2006-05-31 | |
| PCT/US2007/012768 WO2007142986A2 (en) | 2006-05-31 | 2007-05-30 | Aminothiazole derivatives and their uses as antibacterial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140055T1 true HRP20140055T1 (hr) | 2014-02-14 |
Family
ID=38645676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140055TT HRP20140055T1 (hr) | 2006-05-31 | 2014-01-17 | Derivati aminotiazola i njihove uporabe kao antibakterijskog sredstva |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7851439B2 (hr) |
| EP (2) | EP2044101B1 (hr) |
| JP (1) | JP5351014B2 (hr) |
| KR (1) | KR101061658B1 (hr) |
| CN (2) | CN102399260B (hr) |
| AR (1) | AR060977A1 (hr) |
| AU (1) | AU2007255025B2 (hr) |
| BR (1) | BRPI0711885A2 (hr) |
| CA (1) | CA2650133A1 (hr) |
| CL (1) | CL2007001542A1 (hr) |
| CR (1) | CR10430A (hr) |
| DK (1) | DK2044101T3 (hr) |
| EC (1) | ECSP088922A (hr) |
| ES (1) | ES2441993T3 (hr) |
| HK (1) | HK1127614A1 (hr) |
| HR (1) | HRP20140055T1 (hr) |
| IL (1) | IL194880A (hr) |
| MA (1) | MA30485B1 (hr) |
| MX (1) | MX2008015216A (hr) |
| MY (1) | MY146920A (hr) |
| NO (1) | NO20085032L (hr) |
| NZ (1) | NZ572154A (hr) |
| PE (2) | PE20080103A1 (hr) |
| PL (1) | PL2044101T3 (hr) |
| PT (1) | PT2044101E (hr) |
| RU (1) | RU2450015C2 (hr) |
| SI (1) | SI2044101T1 (hr) |
| TN (1) | TNSN08496A1 (hr) |
| TW (2) | TW201107337A (hr) |
| UA (1) | UA95627C2 (hr) |
| WO (1) | WO2007142986A2 (hr) |
| ZA (1) | ZA200808449B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080103A1 (es) | 2006-05-31 | 2008-04-03 | Novartis Ag | AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu |
| MX2009006745A (es) | 2006-12-20 | 2009-08-19 | Novartis Ag | Macrociclos de amino-tiazol, su uso como compuestos anti-bacterianos y procesos para su produccion. |
| KR101202483B1 (ko) * | 2007-06-04 | 2012-11-16 | 노파르티스 아게 | 거대고리 및 그의 용도 |
| AU2012261611B2 (en) * | 2007-12-12 | 2014-05-15 | Novartis Ag | Aminothiazoles and their uses |
| CN101945866B (zh) * | 2007-12-12 | 2013-06-19 | 诺瓦提斯公司 | 氨基噻唑化合物及其用途 |
| WO2014167371A1 (en) * | 2013-04-12 | 2014-10-16 | Naicons S.C.A.R.L. | Analogs of the antibiotic aminothiazole ge2270 |
| CN106366168B (zh) * | 2016-08-26 | 2020-09-15 | 上海交通大学 | 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法 |
| CN107243008B (zh) * | 2017-04-13 | 2021-03-30 | 中国科学院广州生物医药与健康研究院 | 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物 |
| CN113219078B (zh) * | 2021-03-25 | 2022-12-16 | 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） | 一种生活用纸制品中17种有机抗菌剂快速筛查方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202241A (en) | 1988-09-09 | 1993-04-13 | Gruppo Lepetit S.P.A. | Antibiotic GE 2270 |
| ES2066914T3 (es) | 1989-07-04 | 1995-03-16 | Lepetit Spa | Factores a1, a2, a3 y h del antibiotico ge 2270. |
| DE69108972T2 (de) | 1990-03-08 | 1995-10-19 | Lepetit Spa | Antibiotika GE 2270 Faktoren B1, B2, C1, D1, D2, E und T. |
| IL100572A (en) * | 1991-01-03 | 1997-01-10 | Lepetit Spa | Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them |
| DE69224497T2 (de) | 1991-08-30 | 1998-07-02 | Biosearch Italia Spa | Faktor C2a des Antibiotikums CE 2270 |
| US5882900A (en) | 1992-09-10 | 1999-03-16 | Gruppo Lepetit S.P.A. | Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium |
| DK0675900T3 (da) | 1992-12-22 | 1998-03-09 | Biosearch Italia Spa | Antibiotika GE 37468 A, B og C |
| AU3805295A (en) | 1994-11-08 | 1996-05-31 | Gruppo Lepetit S.P.A. | Microbial transformation process for obtaining antibiotic ge 2270 factor d2 |
| DK0801655T3 (da) | 1995-02-07 | 1999-02-08 | Biosearch Italia Spa | Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika |
| ES2161344T3 (es) | 1995-02-07 | 2001-12-01 | Biosearch Italia Spa | Derivados oxazolin-amidicos basicos de los antibioticos ge2270 y similares. |
| ATE231163T1 (de) * | 1996-02-14 | 2003-02-15 | Biosearch Italia Spa | Derivate des antibiotisch wirkenden faktors ge2270 |
| JPH1059997A (ja) * | 1996-08-22 | 1998-03-03 | Microbial Chem Res Found | アミチアマイシンアミド誘導体 |
| KR20050026401A (ko) * | 2002-06-17 | 2005-03-15 | 비큐론 파마세티컬스 인코포레이티드 | 여드름 치료를 위한 ｇｅ 2270 인자 ａ3의 아미드유도체의 용도 |
| CA2580882A1 (en) | 2004-09-22 | 2006-08-17 | Merck & Co., Inc. | Antibiotic compound |
| PE20080103A1 (es) * | 2006-05-31 | 2008-04-03 | Novartis Ag | AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu |
| CN101945866B (zh) * | 2007-12-12 | 2013-06-19 | 诺瓦提斯公司 | 氨基噻唑化合物及其用途 |
-
2007
- 2007-05-29 PE PE2007000664A patent/PE20080103A1/es not_active Application Discontinuation
- 2007-05-29 AR ARP070102300A patent/AR060977A1/es unknown
- 2007-05-29 PE PE2012000528A patent/PE20121011A1/es not_active Application Discontinuation
- 2007-05-30 CA CA002650133A patent/CA2650133A1/en not_active Abandoned
- 2007-05-30 US US11/755,481 patent/US7851439B2/en active Active
- 2007-05-30 CN CN201110384145.2A patent/CN102399260B/zh not_active Expired - Fee Related
- 2007-05-30 CN CNA2007800198364A patent/CN101454337A/zh active Pending
- 2007-05-30 EP EP07795502.9A patent/EP2044101B1/en active Active
- 2007-05-30 TW TW099141102A patent/TW201107337A/zh unknown
- 2007-05-30 TW TW096119338A patent/TWI342310B/zh not_active IP Right Cessation
- 2007-05-30 NZ NZ572154A patent/NZ572154A/en not_active IP Right Cessation
- 2007-05-30 BR BRPI0711885-6A patent/BRPI0711885A2/pt not_active Application Discontinuation
- 2007-05-30 ES ES07795502.9T patent/ES2441993T3/es active Active
- 2007-05-30 RU RU2008150785/04A patent/RU2450015C2/ru not_active IP Right Cessation
- 2007-05-30 UA UAA200811756A patent/UA95627C2/ru unknown
- 2007-05-30 MY MYPI20084727A patent/MY146920A/en unknown
- 2007-05-30 DK DK07795502.9T patent/DK2044101T3/da active
- 2007-05-30 KR KR1020087029296A patent/KR101061658B1/ko active IP Right Grant
- 2007-05-30 EP EP10179066A patent/EP2322536A3/en not_active Withdrawn
- 2007-05-30 MX MX2008015216A patent/MX2008015216A/es active IP Right Grant
- 2007-05-30 PL PL07795502T patent/PL2044101T3/pl unknown
- 2007-05-30 AU AU2007255025A patent/AU2007255025B2/en not_active Ceased
- 2007-05-30 CL CL200701542A patent/CL2007001542A1/es unknown
- 2007-05-30 PT PT77955029T patent/PT2044101E/pt unknown
- 2007-05-30 JP JP2009513260A patent/JP5351014B2/ja not_active Expired - Fee Related
- 2007-05-30 WO PCT/US2007/012768 patent/WO2007142986A2/en active Application Filing
- 2007-05-30 SI SI200731371T patent/SI2044101T1/sl unknown
-
2008
- 2008-10-03 ZA ZA2008/08449A patent/ZA200808449B/en unknown
- 2008-10-23 IL IL194880A patent/IL194880A/en active IP Right Grant
- 2008-11-10 CR CR10430A patent/CR10430A/es unknown
- 2008-11-28 TN TNP2008000496A patent/TNSN08496A1/en unknown
- 2008-11-28 EC EC2008008922A patent/ECSP088922A/es unknown
- 2008-12-01 MA MA31428A patent/MA30485B1/fr unknown
- 2008-12-02 NO NO20085032A patent/NO20085032L/no unknown
-
2009
- 2009-07-20 HK HK09106606.4A patent/HK1127614A1/xx not_active IP Right Cessation
-
2010
- 2010-07-01 US US12/828,737 patent/US20100267757A1/en not_active Abandoned
-
2014
- 2014-01-17 HR HRP20140055TT patent/HRP20140055T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140055T1 (hr) | Derivati aminotiazola i njihove uporabe kao antibakterijskog sredstva | |
| DE60221684T2 (de) | Antibiotika mit doppelwirkung | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
| CA2472372A1 (en) | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| MXPA05003119A (es) | Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas. | |
| BR1100981A (pt) | Composto, e, composição farmacêutica | |
| WO2005000863A3 (en) | 6, 11-4c-bicyclic 9a-azalide derivatives | |
| HRP20090629T1 (hr) | Aminoacil-prolijek derivati i lijekovi za liječenje tromboemboličkih poremećaja | |
| DE60331056D1 (de) | 6-11 bicyclische ketolidderivate | |
| JP2009514894A5 (hr) | ||
| IL189017A0 (en) | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-effective agents | |
| TW200634021A (en) | 3,6-bicyclolides | |
| WO2005070113A3 (en) | 9n-substituted 6-11 bicyclic erythromycin derivatives | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20120634T1 (hr) | Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba | |
| CA2483875A1 (en) | 6,11 bicyclic erythromycin derivatives | |
| WO2006065721A3 (en) | 11, 12-lactone bicyclolides | |
| EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| WO2007044927A3 (en) | 6, 11-bridged tricyclic macrolides | |
| WO2008028805A3 (de) | Verwendung einer pharmazeutischen zusammensetzung enthaltend ein anticholinergikum zur abtötung von mikroorganismen und zur behandlung von atemwegsinfektionen | |
| JP2024009968A5 (hr) | ||
| WO2006065743A3 (en) | Tetracylic bicyclolides | |
| KR950701921A (ko) | 피리딘 화합물 및 이의 제약학적 용도(pyridine compound and medicinal use thereof) |